CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$7.06M |
| 3 |
NVIDIA
NVDA
|
$6.46M |
| 4 |
Microsoft
MSFT
|
$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
$5.72M |
| 2 |
GSK
GSK
|
$5.14M |
| 3 |
Pinduoduo
PDD
|
$3.46M |
| 4 |
Procter & Gamble
PG
|
$2.91M |
| 5 |
Synopsys
SNPS
|
$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Axon Enterprise
AXON
$57.2B
| $738K | 0.07% |
+1,241
| New | +$738K |
|
202
Avidity Biosciences
RNA
$6.48B
| $736K | 0.07% |
25,298
+2,772
| +12% | +$80.6K |
|
203
lululemon athletica
LULU
$19.9B
| $732K | 0.07% |
1,915
-3,168
| -62% | -$1.21M |
|
204
Rhythm Pharmaceuticals
RYTM
$6.78B
| $729K | 0.07% |
13,031
+1,273
| +11% | +$71.3K |
|
205
SPDR S&P Biotech ETF
XBI
$5.39B
| $722K | 0.07% |
8,022
-15,101
| -65% | -$1.36M |
|
206
Li Auto
LI
$24B
| $720K | 0.07% |
30,000
-5,000
| -14% | -$120K |
|
207
Supernus Pharmaceuticals
SUPN
$2.58B
| $718K | 0.07% |
19,866
+9,267
| +87% | +$335K |
|
208
CRISPR Therapeutics
CRSP
$4.99B
| $712K | 0.07% |
18,098
+1,717
| +10% | +$67.6K |
|
209
Keurig Dr Pepper
KDP
$38.9B
| $709K | 0.07% |
22,075
+4,874
| +28% | +$157K |
|
210
IQVIA
IQV
$31.9B
| $688K | 0.06% |
3,500
| – | – |
|
211
NovoCure
NVCR
$1.37B
| $684K | 0.06% |
22,943
+2,129
| +10% | +$63.4K |
|
212
Wave Life Sciences
WVE
$1.32B
| $671K | 0.06% |
54,267
+30,276
| +126% | +$375K |
|
213
Fastenal
FAST
$55.1B
| $670K | 0.06% |
18,646
+4,120
| +28% | +$148K |
|
214
Baker Hughes
BKR
$44.9B
| $661K | 0.06% |
16,104
+3,503
| +28% | +$144K |
|
215
Veracyte
VCYT
$2.55B
| $651K | 0.06% |
16,433
+1,660
| +11% | +$65.7K |
|
216
Acadia Pharmaceuticals
ACAD
$4.26B
| $647K | 0.06% |
35,281
+3,378
| +11% | +$62K |
|
217
Xenon Pharmaceuticals
XENE
$3.02B
| $634K | 0.06% |
16,166
+1,594
| +11% | +$62.5K |
|
218
Verisk Analytics
VRSK
$37.8B
| $633K | 0.06% |
2,298
+491
| +27% | +$135K |
|
219
Xcel Energy
XEL
$43B
| $631K | 0.06% |
9,345
+2,274
| +32% | +$154K |
|
220
Zeta Global
ZETA
$4.5B
| $630K | 0.06% |
+35,000
| New | +$630K |
|
221
Electronic Arts
EA
$42.2B
| $624K | 0.06% |
4,268
+917
| +27% | +$134K |
|
222
Denali Therapeutics
DNLI
$2.26B
| $622K | 0.06% |
30,517
+2,982
| +11% | +$60.8K |
|
223
Cognizant
CTSH
$35.1B
| $621K | 0.06% |
8,069
+1,782
| +28% | +$137K |
|
224
Exelon
EXC
$43.9B
| $616K | 0.06% |
16,353
+3,663
| +29% | +$138K |
|
225
Old Dominion Freight Line
ODFL
$31.7B
| $613K | 0.06% |
3,474
+756
| +28% | +$133K |
|